Each normal organ and pathological condition contains organ-or disease-specific molecular tags on its vasculature that constitute a vascular 'zip code' system. Tissue-selective tumour metastasis may also depend on vascular addresses. We have used phage display peptide libraries to map disease-specific differences in the vasculature. By using this technology, we have isolated several peptides which are targeted specifically to tumour blood vessels, lymphatic vessels and/or tumour cells. Some of the tumour-homing peptides recognize common angiogenesis markers and are capable of binding to several types of tumour, whereas other peptides recognize tumour-type-specific differences. We have also shown that the vasculature of a premalignant lesion differs from that of a full-blown tumour and also from the vasculature of the corresponding normal organ. Our peptides have revealed molecules that act as novel biomarkers of this vascular heterogeneity. Interestingly, some of our homing peptides are able to penetrate the target cells. This internalization differs from that of the Tat, penetratins and other related peptides in that our peptides enter the cell in a celltype-specific manner. These peptides appear to be able to concentrate in the target tissue, making them particularly efficient delivery vectors for the targeting of drugs, other therapeutic moieties and imaging agents.
Background
It has become evident that vascular beds in each individual normal organ, as well as vascular beds involved in pathological conditions, are highly specialized [1] . In vivo biopanning using phage display peptide libraries is a powerful tool to demonstrate this vascular heterogeneity and identify peptide ligands against vascular markers selectively expressed by either normal [2] [3] [4] [5] or tumour [6] [7] [8] [9] [10] endothelium. In order to identify homing peptides using the in vivo phage display technology, the phage library is injected into the tail vein of a mouse and allowed the phage to circulate for 5-15 min followed by recovery and amplification of the phage bound to the vasculature of the target organ. Repeating the selection procedure twice allows the enrichment for phages that displayed specific peptides, which have an increased affinity for the target tissue. The phage technology enables the detection of both differentially expressed molecules and also differentially modified molecules (e.g. glycosylation, phosphorylation and methylation). Furthermore, this technology does not require any previous knowledge of the molecular composition at the site of interest. The peptides homing to specific vascular addresses have revealed novel tissue-specific biomarkers of diseased and normal vasculature. Some of these molecules are general markers of angiogenesis which are expressed on all types of angiogenic blood vessel. The integrin αvβ3 [9] , aminopeptidase N [8] and nucleolin [10, 11] are examples of this type of angiogenic marker. In contrast, some peptides recognize markers that are tumour-type-specific, suggesting that different tumours express a distinct range of molecular markers on their vasculature [7, [12] [13] [14] . In addition, we have shown that the vasculature changes during tumour progression, and that vasculature of the pre-malignant and fully malignant lesions can be distinguished from each other and from the normal vasculature [14, 15] .
The increasing collection of homing peptides which can recognize blood vascular or lymphatic 'zip codes' expressed on the endothelium can be divided roughly into three subclasses according to their activities.
(1) Peptides which are targeted to a specific site (homing to desired location, recognition molecule on the cell surface, no internalization of the peptide).
(2) Peptides which are capable of targeting and internalization (homing and cell uptake via a recognition molecule, useful for targeted therapies or imaging purposes when conjugated to a drug/detectable label).
(3) Peptides which are capable of targeting, internalization and destruction (all performed by the same peptide sequence).
Homing peptides with cell-penetrating properties
Discovery of homing peptides by means of in vivo phage display sometimes yields peptides with surprising, yet beneficial, properties -for example, a peptide capable of both homing and internalization.
The first tumour-homing peptides discovered which possessed internalization properties were the RGD (Arg-Gly-Asp) peptides. These peptides recognize a family of cell-surface receptors, integrins, which mediate the interaction of cells with the ECM (extracellular matrix) components fibronectin and type I collagen and are important for the migration and invasion of tumour cells [9, 16] . It has been shown that phage particles displaying the RGD sequence on their surface are internalized efficiently, presumably either by receptor-mediated endocytosis or a phagocytosis-like process [17] . Moreover, αvβ3 and αvβ5 integrins are known to promote internalization of adenoviruses [18] , defining this pathway as a possible cell-penetrating pathway.
Another peptide with internalizing properties recognizes HNSCC (human head and neck squamous cell cancer) tumours. This peptide, HN-1, is able to internalize into both cultured HNSCC cells and tumour cells within HNSCC xenografts. The mechanism of internalization used for the HN-1 peptide is unknown [19] .
F3, a 31-amino-acid peptide encoding the N-terminal fragment of HMNG-2 (human high-mobility group protein-2), was isolated by screening a phage display cDNA library, first ex vivo for binding to bone marrow cells followed by in vivo screening for homing to HL-60 (human myeloid leukaemia) xenografts in mice. Fluorescein-conjugated F3 binds to both tumour cells and tumour-associated blood endothelial cells not only in the leukaemia tumour model, but also in other types of tumour. In addition, the F3 peptide seems to recognize a minor population of progenitor cell-like bone marrow cells [10] . F3 is promising for drug-targeting applications, since it is taken up by the cells and it is able to carry a payload into the target cell nucleus. Cell-surfaceexpressed nucleolin was confirmed to act as a receptor molecule for the F3 peptide. Anti-nucleolin antibodies also recognize blood vessels in a non-malignant angiogenesis model as well as in tumour-associated blood vessels [11] .
LyP-1, a nine-amino-acid cyclic peptide (CGNKRTRGC), was isolated in a screen using human MDA-MB-435 breast cancer xenografts. LyP-1, like F3, recognizes a marker that is shared by the tumour cells and the tumour endothelial cells. However, unlike other vascular homing peptides, LyP-1 recognizes tumour-associated lymphatic vessels [7] . LyP-1 peptide strongly accumulates in the nucleus of both primary tumours and their metastatic lesions after intravenous injections (Figure 1 ). LyP-1 peptide is unique among the tumourhoming peptides, since, in addition to homing and internalization by the lymphatic endothelial cells and tumour cells, LyP-1 also leads to apoptosis of the cells to which it binds. Systemic delivery of LyP-1 peptide to tumour-bearing mice inhibits tumour growth. This striking anti-tumour effect of LyP-1 seems to be due to the cytotoxic activity of the peptide [20] . Specific homing of the LyP-1 peptide to the tumourassociated lymphatic vessels of certain tumours was the first demonstration that tumour lymphatic vessels can differ from normal lymphatic vessels. Zhang et al. [13] later identified a panel of peptides which are targeted to tumour lymphatics, showing that tumour development is associated with organand stage-specific changes in the lymphatic vessels, as has been shown previously for the blood vessels.
Homing peptides can also be used as imaging tools. LyP-1 has been used successfully in tumour imaging by systemic delivery of the fluorescein-conjugated peptide to tumour-bearing mice [20] . The efficient internalization and accumulation of LyP-1 concentrates the fluorescein to the nuclei of the target cells, allowing imaging of tumours.
Moreover, inorganic nanoparticles such as qdots (quantum dots) have provoked interest as potential intravascular probes for imaging and drug delivery. The homing properties of F3 and LyP-1 peptides have been used to target intravenously administered qdots to tumours. Peptide-coated qdots showed spectacular homing specificity for the relevant vascular target site, consistent with previous findings [7, 10] . F3 qdots home to the blood vessels and LyP-1 qdots to the lymphatic vessels in the same tumour. Unlike fluorescein-coupled homing peptides, which freely penetrate the tissue, peptide-coated qdots were not found outside the vasculature in the parenchyma of the target tissue. The prohibited tissue penetration is presumably due to the relatively large size of the peptide-coated qdot particles [21] .
The pentapeptide CGKRK is another tumour-homing peptide that was identified when a screen of peptides homing to a mouse model of squamous cell carcinoma was performed. The CGKRK peptide can home to all types of tumour tested and is capable of entering the target cell nucleus. Internalization of CGKRK is thought to be due to binding of the peptide to heparan sulfates at the cell surface [14] .
F3, LyP-1 and CGKRK peptides are all basic in nature, resembling CPPs (cell-penetrating peptides) such as Tat and penetratin [22] . However, there is an important distinction between the canonical CPPs and our tumour-homing peptides: the cellular uptake of the homing peptides appears to be an energy-dependent and cell-type-specific process.
Chimaeric peptides (homing peptides conjugated to therapeutic molecules)
One application of homing peptides is their use in targeted therapy in which the properties of a known homing peptide are combined with a toxin or a pro-drug molecule. Targeted therapy restricts the toxic effect of a drug to the malignant tissues, thereby increasing the efficacy and decreasing the undesired side effects of the drug. The RGD tumour-homing sequence that recognizes the αv integrins has been widely used to deliver cytotoxic compounds selectively to tumour cells and tumour-related vasculature. αv integrins are also upregulated in angiogenic endothelial cells, making them attractive targets for targeted drug therapy [23] . A drug-shuttle created by conjugating dox (doxorubicin), one of the most widely used anticancer drugs, to the RGD tumour-homing domain was used to treat MDA-MB-435 breast cancer xenograft-bearing mice. Compared with mice receiving either free dox or dox coupled to a control peptide, mice treated with RGD-coupled dox lived longer and had fewer pulmonary metastases. Similar results were obtained using the NGR (Asn-Gly-Arg) tumour-homing peptide conjugated to dox [24] .
Another study utilized the RGD and NGR domains as targeting platforms by combining them to TNF (tumour necrosis factor) to create a toxin. Systemic administration of RGD-TNF or NGR-TNF resulted in inhibition of tumour growth in B16 melanoma-and RMA-T lymphoma-bearing mice. The anti-tumour effect of TNF is well known. However, the therapeutic properties of TNF were enhanced when the protein was linked to the tumour-homing peptides [25] .
Peptide-driven delivery of the apoptosis-promoting peptide (KLAKLAK) 2 [26] has also been applied in medical prostatectomies and the treatment of arthritis. (KLAKLAK) 2 is an antimicrobial peptide which is harmless outside the cell, but becomes toxic when internalized as it causes disruption of the mitochondrial membrane, leading to programmed cell death [26] . The heptapeptide SMSIARL was isolated from a phage display peptide library and specifically targets the prostate vasculature. When SMSIARL is coupled to (KLAKLAK) 2 , tissue destruction is observed exclusively in the prostate. This chimaeric peptide postpones cancer development in prostate-cancer-prone transgenic TRAMP (transgenic adenocarcinoma of the mouse prostate model) mice [27] , thereby offering a possible alternative for treatment of prostate hypertrophy and a reduction in the future cancer risk based on vascular targeted therapy [2] . Also, (KLAKLAK) 2 peptide has been used to treat inflammatory arthritis when linked to the RGD peptide. Intravenously injected RGDC 4 D(KLAKLAK) 2 peptides reduced clinical arthritis in a collagen-induced murine model and increased apoptosis in synovial vessels, whereas treatment with vehicle or an uncoupled mixture of the RGDC 4 and (KLAKLAK) 2 peptides had no effect [28] . Furthermore, (KLAKLAK) 2 conjugated to the RGD homing peptide has been used to selectively reduce the tumour burden in a pre-clinical cancer model. This targeted pro-drug is specifically toxic to angiogenic endothelial cells and displays anticancer properties when administered to mice [29] .
The detailed mechanism of action regarding several of the targeting chimaeras is not fully understood. On observation of the anti-tumour effect followed by the administration of the peptides, it is likely that binding of the peptide to a surface receptor and the introduction of the toxin to the cells leads to disruption of the target tissue. Therefore internalization might not be necessary for targeted therapy, but it is likely to contribute to the effectiveness of the peptide to concentrate into targeted tissue.
Concluding remarks
Vascular profiling using the in vivo phage display technology has revealed surprising molecular diversity in the vascular beds of both normal and diseased tissues. In addition, premalignant vasculature (both blood and lymphatic vasculature) differs from that of a full-blown tumour, suggesting that vascular evolution occurs during tumour progression. Some homing peptides are capable of entering their target cells in a cell-type-specific manner and carrying a payload into these cells. In one example, a tumour-homing peptide has a cytotoxic activity in addition to the homing and internalizing properties displayed by the peptide.
Identification of markers expressed by the malignancy-associated vasculature would help to direct the cytotoxic effect to the site of disease and protect healthy tissue. As suggested from previous work, it may be possible to develop site-directed anticancer strategies that are based on selective expression of receptors on tumour cells and tumour-related vasculature. Tumour-homing peptides with the ability to transport cargo to their target cells represent the first front of these future strategies.
